

Motif Bio PLC

12:15 16 Apr 2019

Motif Bio higher as it presents data from Phase III iclaprim trial

Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) shares rose on Tuesday as the firm delivered new data on its lead drug, iclaprim, at the European Congress of Clinical Microbiology and Infectious Diseases, in Amsterdam.

The presentation provided a drill-down into the results from the company's REVIVE Phase III study of people with skin and skin structure infections.

READ: Motif Bio receives vote of confidence as it raises £2.7m
Among the headlines was an analysis by lesion size, which showed the antibiotic had comparable efficacy to vancomycin, the current standard of care.

Delegates heard the bacteremia rates were comparable between the two drugs, while the pharmacokinetics of iclaprim (the way the drug moves around the body) supported the use of a fixed dosing regimen.

Finally, Motif provided details of a recent lab-based data supporting iclaprim's activity against Gram-positive bacteria collected from patients.

"Data are being presented that show that iclaprim continues to be active against a variety of antibiotic-resistant pathogens like methicillin-resistant (MRSA), methicillin-susceptible (MSSA) Staphylococcus aureus, and other Gram-positive skin and soft structure pathogens collected during 2017 from Europe and the US," Motif said.

In early afternoon trading in London, Motif Bio shares were 4.9% higher at 8.82p.

-- Adds share price --

Price: 7.6p

Market Cap: £26.03M

1 Year Share Price Graph



May 2018 November 2018 May 2019

Share Information

Code: MTFB

Listing: AIM

52 week High Low
44.90p 4.75p

Sector: Pharma & Biotech

Website: www.motifbio.com

Company Synopsis:

Motif Bio PL (LON:MTFB, NASDAQ:MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA. The company's lead product candidate is iclaprim. Motif Bio is seeking approval of iclaprim from the U. S.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.